
Graves’ Ophthalmopathy - Pipeline Insight, 2025
Description
DelveInsight’s, “Graves’ Ophthalmopathy - Pipeline Insight, 2025” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Graves’ Ophthalmopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Graves’ Ophthalmopathy: Overview
Graves' Ophthalmopathy (GO), also known as Graves' Orbitopathy or Thyroid Eye Disease (TED), is an autoimmune disorder that primarily affects the retro-ocular tissues, often occurring in patients with hyperthyroidism due to Graves' disease. However, it can also sporadically develop in patients who are euthyroid or hypothyroid, particularly those with chronic autoimmune thyroiditis. This condition is characterized by a constellation of signs and symptoms, including eye bulging, double vision, and inflammation, which can be sight-threatening in its severe form. GO has an annual incidence rate of 16 women and 3 men per 100,000 population. Despite being studied for nearly two centuries, the pathophysiology of Graves' Ophthalmopathy remains complex, with ongoing research into its mechanisms and potential targeted therapies. Prompt diagnosis and management are critical to prevent vision impairment and improve patient outcomes.
Graves' ophthalmopathy (GO) is primarily driven by thyroid-stimulating hormone (TSH) receptor antibodies, which act on TSH receptors found not only in the thyroid but also in various extrathyroidal tissues, including retro-ocular tissues. Studies suggest that TSH receptors are more abundantly expressed in the retro-ocular tissue of patients with Graves' disease, contributing to the development of GO. Several factors increase the risk of orbitopathy in Graves' disease, including higher levels of TSH receptor antibodies, female gender, genetic predispositions (although specific genes remain unidentified), and exposure to radioiodine treatment. Smoking is the most significant modifiable risk factor, exacerbating the severity of GO and reducing the response to treatment by affecting both humoral and cell-mediated immunity.
Thyroid Eye Disease (TED) typically follows a self-limiting course due to the absence of orbital lymphoid tissue, with its natural history divided into phases. The initial phase is characterized by a steep rise in disease severity, lasting from six months to five years, with an average duration of two years. This is followed by an inflammatory phase, during which the disease remains active. After approximately 18 months, TED stabilizes and enters the inactive phase, where regression occurs, although residual fibrotic changes in the orbit persist. Aggressive immunosuppressive treatment during the active phase can limit the destructive and fibrotic effects of the immune process. Once the disease becomes inactive, it is less responsive to medical management, often necessitating surgical intervention.
The treatment of Graves' Ophthalmopathy (GO) is tailored based on disease severity and includes both supportive and specific measures. Supportive care, such as ocular lubrication, eye patches, prism correction for diplopia, and elevating the head of the bed, is essential for all patients. Selenium may benefit those with mild disease in selenium-deficient areas, while smoking cessation and achieving euthyroidism are crucial. Medical treatments for moderate-to-severe disease include glucocorticoids, with intravenous methylprednisolone preferred for severe cases, though side effects require careful monitoring. Second-line options include immunomodulators like rituximab, mycophenolate, external orbital radiation, and orbital decompression surgery. Teprotumumab, an IGF-1 receptor antagonist, has shown promise in clinical trials for moderate-to-severe active disease. In sight-threatening cases, immediate hospitalization with intravenous glucocorticoids and potential urgent orbital decompression surgery is required. Surgical options, including orbital decompression and corrective procedures for lid retraction and muscle restriction, are considered for those who do not respond to medical management. In children and pregnant patients, the treatment approach is adapted to minimize risks, with antithyroid drugs being the primary therapy, and steroids or surgery reserved for severe cases. Radiation therapy is generally avoided due to its side effects, especially in pediatric and pregnant populations.
""Graves’ Ophthalmopathy- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Graves’ Ophthalmopathy pipeline landscape is provided which includes the disease overview and Graves’ Ophthalmopathy treatment guidelines. The assessment part of the report embraces, in depth Graves’ Ophthalmopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Graves’ Ophthalmopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Graves’ Ophthalmopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Graves’ Ophthalmopathy Emerging Drugs
Further product details are provided in the report……..
Graves’ Ophthalmopathy: Therapeutic Assessment
This segment of the report provides insights about the different Graves’ Ophthalmopathy drugs segregated based on following parameters that define the scope of the report, such as:
Graves’ Ophthalmopathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Graves’ Ophthalmopathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Graves’ Ophthalmopathy drugs.
Graves’ Ophthalmopathy Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Graves’ Ophthalmopathy: Overview
Graves' Ophthalmopathy (GO), also known as Graves' Orbitopathy or Thyroid Eye Disease (TED), is an autoimmune disorder that primarily affects the retro-ocular tissues, often occurring in patients with hyperthyroidism due to Graves' disease. However, it can also sporadically develop in patients who are euthyroid or hypothyroid, particularly those with chronic autoimmune thyroiditis. This condition is characterized by a constellation of signs and symptoms, including eye bulging, double vision, and inflammation, which can be sight-threatening in its severe form. GO has an annual incidence rate of 16 women and 3 men per 100,000 population. Despite being studied for nearly two centuries, the pathophysiology of Graves' Ophthalmopathy remains complex, with ongoing research into its mechanisms and potential targeted therapies. Prompt diagnosis and management are critical to prevent vision impairment and improve patient outcomes.
Graves' ophthalmopathy (GO) is primarily driven by thyroid-stimulating hormone (TSH) receptor antibodies, which act on TSH receptors found not only in the thyroid but also in various extrathyroidal tissues, including retro-ocular tissues. Studies suggest that TSH receptors are more abundantly expressed in the retro-ocular tissue of patients with Graves' disease, contributing to the development of GO. Several factors increase the risk of orbitopathy in Graves' disease, including higher levels of TSH receptor antibodies, female gender, genetic predispositions (although specific genes remain unidentified), and exposure to radioiodine treatment. Smoking is the most significant modifiable risk factor, exacerbating the severity of GO and reducing the response to treatment by affecting both humoral and cell-mediated immunity.
Thyroid Eye Disease (TED) typically follows a self-limiting course due to the absence of orbital lymphoid tissue, with its natural history divided into phases. The initial phase is characterized by a steep rise in disease severity, lasting from six months to five years, with an average duration of two years. This is followed by an inflammatory phase, during which the disease remains active. After approximately 18 months, TED stabilizes and enters the inactive phase, where regression occurs, although residual fibrotic changes in the orbit persist. Aggressive immunosuppressive treatment during the active phase can limit the destructive and fibrotic effects of the immune process. Once the disease becomes inactive, it is less responsive to medical management, often necessitating surgical intervention.
The treatment of Graves' Ophthalmopathy (GO) is tailored based on disease severity and includes both supportive and specific measures. Supportive care, such as ocular lubrication, eye patches, prism correction for diplopia, and elevating the head of the bed, is essential for all patients. Selenium may benefit those with mild disease in selenium-deficient areas, while smoking cessation and achieving euthyroidism are crucial. Medical treatments for moderate-to-severe disease include glucocorticoids, with intravenous methylprednisolone preferred for severe cases, though side effects require careful monitoring. Second-line options include immunomodulators like rituximab, mycophenolate, external orbital radiation, and orbital decompression surgery. Teprotumumab, an IGF-1 receptor antagonist, has shown promise in clinical trials for moderate-to-severe active disease. In sight-threatening cases, immediate hospitalization with intravenous glucocorticoids and potential urgent orbital decompression surgery is required. Surgical options, including orbital decompression and corrective procedures for lid retraction and muscle restriction, are considered for those who do not respond to medical management. In children and pregnant patients, the treatment approach is adapted to minimize risks, with antithyroid drugs being the primary therapy, and steroids or surgery reserved for severe cases. Radiation therapy is generally avoided due to its side effects, especially in pediatric and pregnant populations.
""Graves’ Ophthalmopathy- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Graves’ Ophthalmopathy pipeline landscape is provided which includes the disease overview and Graves’ Ophthalmopathy treatment guidelines. The assessment part of the report embraces, in depth Graves’ Ophthalmopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Graves’ Ophthalmopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Graves’ Ophthalmopathy R&D. The therapies under development are focused on novel approaches to treat/improve Graves’ Ophthalmopathy.
This segment of the Graves’ Ophthalmopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Graves’ Ophthalmopathy Emerging Drugs
- IBI311: Innovent Biologics (Suzhou) Co. Ltd.
- VRDN-001: Viridian Therapeutics, Inc.
- Lonigutamab: ACELYRIN Inc.
- KRIYA 586: Kriya Therapeutics
Further product details are provided in the report……..
Graves’ Ophthalmopathy: Therapeutic Assessment
This segment of the report provides insights about the different Graves’ Ophthalmopathy drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Graves’ Ophthalmopathy
- There are approx. 15+ key companies which are developing the therapies for Graves’ Ophthalmopathy. The companies which have their Graves’ Ophthalmopathy drug candidates in the most advanced stage, i.e. Phase II include, Innovent Biologics (Suzhou) Co. Ltd.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Graves’ Ophthalmopathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Graves’ Ophthalmopathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Graves’ Ophthalmopathy drugs.
Graves’ Ophthalmopathy Report Insights
- Graves’ Ophthalmopathy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Graves’ Ophthalmopathy drugs?
- How many Graves’ Ophthalmopathy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Graves’ Ophthalmopathy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Graves’ Ophthalmopathy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Graves’ Ophthalmopathy and their status?
- What are the key designations that have been granted to the emerging drugs?
- Innovent Biologics (Suzhou) Co. Ltd.
- Viridian Therapeutics, Inc.
- ACELYRIN Inc.
- Kriya Therapeutics
- Tourmaline Bio, Inc.
- Sinocelltech Ltd.
- Hoffmann-La Roche
- Immunovant Sciences GmbH
- H. Lundbeck A/S
- Sling Therapeutics, Inc.
- Lassen Therapeutics Inc.
- Changchun GeneScience Pharmaceutical Co., Ltd.
- argenx
- Amgen
- Minghui Pharmaceutical (Shanghai)
- IBI311
- VRDN-001
- Lonigutamab
- KRIYA 586
- TOUR006
- SCTT11
- Satralizumab
- Batoclimab
- Lu AG22515
- Linsitinib
- LASN01
- GenSci098
- Efgartigimod
- AMG 732
- MHB 018A
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Graves’ Ophthalmopathy: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Graves’ Ophthalmopathy– DelveInsight’s Analytical Perspective
- Late Stage Products (Registration)
- Comparative Analysis
- IBI311: Innovent Biologics (Suzhou) Co. Ltd.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- Lonigutamab: ACELYRIN Inc.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- KRIYA 586: Kriya Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Graves’ Ophthalmopathy Key Companies
- Graves’ Ophthalmopathy Key Products
- Graves’ Ophthalmopathy- Unmet Needs
- Graves’ Ophthalmopathy- Market Drivers and Barriers
- Graves’ Ophthalmopathy- Future Perspectives and Conclusion
- Graves’ Ophthalmopathy Analyst Views
- Graves’ Ophthalmopathy Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.